Scarica l'app Stockscreener
83.83
1.18%
-1.00
Dopo l'orario di chiusura:
83.08
-0.75
-0.89%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Perché AZN Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Astrazeneca PLC Borsa (AZN) Ultime notizie
AstraZeneca PLC Depositary Receipt stock momentum explainedWeekly Market Outlook & High Accuracy Buy Signal Tips - newser.com
Pattern recognition hints at AstraZeneca PLC Depositary Receipt upsideQuarterly Earnings Report & Technical Confirmation Trade Alerts - newser.com
UK Finance Minister Seeks More Pharma InvestmentAstraZeneca (NASDAQ:AZN), Merck & Co (NYSE:MRK) - Benzinga
AstraZeneca doubles Lokelma output with $445m Texas plant expansion - Pharmaceutical Technology
AstraZeneca falls, with Deutsche Bank more skeptical - MarketScreener
Merck's Keytruda Plus Chemo Regimen Shows Overall Survival Benefit In Recurrent Ovarian Cancer Patients - Benzinga
AstraZeneca (AZN) Lung Cancer Trial Highlights New Diagnostic To - GuruFocus
Immunai agreement to advance an inflammatory bowel disease target with AstraZeneca - MarketScreener
AstraZeneca (AZN): Lynparza's Role in Ovarian Cancer Treatment - GuruFocus
AstraZeneca Gets Rare Sell as Deutsche Bank Has Pipeline Worries - Bloomberg.com
AstraZeneca doubles Lokelma production at its Texas facility - MarketScreener
AstraZeneca downgraded by leading investment bank. Here's why - Proactive financial news
AstraZeneca’s White House Deal: Policy Relief, Margin Risks & A $50 Billion U.S. Bet! - Smartkarma
AstraZeneca joins Pfizer in most-favored nation pricing program - TechTarget
Trump Locks In AstraZeneca Deal to Slash Medicaid Drug Prices -- Big Pharma Faces New Reality - GuruFocus
AstraZeneca PLC Depositary Receipt recovery potential after sell offNew Guidance & Safe Entry Point Identification - newser.com
AstraZeneca (AZN) Expands Coppell Facility to Boost Lokelma Prod - GuruFocus
AstraZeneca Boosts U.S. Manufacturing with Texas Facility Expansion - MarketScreener
$445M expansion: AstraZeneca doubles Lokelma production at Coppell, adds 9,000 sq ft - Stock Titan
AstraZeneca cuts US drug pricing deal; FDA declares Novo plant out of compliance - BioPharma Dive
AstraZeneca opens expanded facility in Texas - breakingthenews.net
AstraZeneca’s US listing plan backed by key shareholder advisers - The Times
Astrazeneca (AZN) is a Top-Ranked Growth Stock: Should You Buy? - Yahoo Finance
Is AstraZeneca PLC Depositary Receipt stock ready for a breakoutMarket Sentiment Report & Daily Stock Trend Reports - newser.com
AstraZeneca reaches agreement with US government to reduce drug prices - Investing.com
Will breakout in AstraZeneca PLC Depositary Receipt lead to full recovery2025 Volume Leaders & Accurate Technical Buy Alerts - newser.com
AstraZeneca reaches agreement with US government to reduce drug prices By Investing.com - Investing.com South Africa
Goldman Sachs Sticks to Their Buy Rating for AstraZeneca (AZN) - The Globe and Mail
UBS Keeps Their Buy Rating on AstraZeneca (AZN) - The Globe and Mail
Advanced analytics toolkit walkthrough for AstraZeneca PLC Depositary ReceiptJuly 2025 Reactions & Momentum Based Trading Ideas - newser.com
Barclays Says AstraZeneca's US Drug Pricing Deal 'Strategically Constructive' - 富途牛牛
Astrazeneca to lower US prices amid Trump squeeze - MarketScreener
Trump Strikes Again: AstraZeneca's Surprise Drug Deal Could Shake Big Pharma's Global Pricing Power - TradingView
AZN Strikes Drug Pricing Deal With Trump, Gets 3-Year Tariff Reprieve - The Globe and Mail
Why AstraZeneca PLC Depositary Receipt stock remains undervaluedWeekly Stock Recap & Target Return Focused Picks - newser.com
How to monitor AstraZeneca PLC Depositary Receipt with trend dashboardsMarket Growth Summary & Real-Time Chart Breakout Alerts - newser.com
Global markets live: Blackstone, Pfizer, Tesla, Stellantis, AstraZeneca… - MarketScreener
Will AstraZeneca PLC Depositary Receipt bounce back from current supportJuly 2025 Earnings & Real-Time Sentiment Analysis - newser.com
AstraZeneca (AZN) Agrees to Lower Drug Prices in the U.S. with S - GuruFocus
AstraZeneca's drug pricing deal with Trump far from clear result, say analysts - Proactive financial news
AstraZeneca inks Trump drug pricing deal amid tariff threats - Pharmaceutical Technology
AstraZeneca PLC (AZN) Stock Analysis: 6.2% Potential Upside Fuels Investor Interest - DirectorsTalk Interviews
AstraZeneca: Drug Pricing Agreement Mitigates Threats of Tariffs and Price Controls - Morningstar Canada
Vanguard Personalized Indexing Management LLC Increases Stock Holdings in AstraZeneca PLC $AZN - MarketBeat
Trending tickers: TSMC, AstraZeneca, Lloyds, Fresnillo and Canal+ - Yahoo
AstraZeneca confirms deal with US government on drug prices - MarketScreener
AstraZeneca reaches agreement with Trump to lower its prices in the US - MarketScreener
AstraZeneca agrees to offer US discounts in exchange for no tariffs - Proactive financial news
AstraZeneca to cut US drug prices in key White House deal - Sharecast.com
AstraZeneca : Agreement with US Govt to lower medicine prices - MarketScreener
Trump announces deal with AstraZeneca on drug prices, tariffs - MarketScreener
AstraZeneca Plc Reaches Agreement With Trump Administration To Cut US Drug Prices - DirectorsTalk Interviews
AstraZeneca Joins US President Trump's Drug-Cost Initiative, Secures Tariff Reprieve - MarketScreener
US FDA Commissioner’s Involvement In AstraZeneca Pricing Deal Raises Ethical, Legal Questions - insights.citeline.com
President Trump announces deal with AstraZeneca on drug prices and tariffs - Taipei Times
Banquets and billions: How AstraZeneca sealed a US medicine deal with Trump - MarketScreener
AstraZeneca PLC $AZN Shares Bought by Aberdeen Group plc - MarketBeat
AstraZeneca PLC $AZN Stock Holdings Lowered by US Bancorp DE - MarketBeat
AstraZeneca Signs US Drug Pricing Deal, Secures Three-year Delay to Tariffs - MarketScreener
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):